I am excited to join Herantis and collaborate with the management and Board to bring the company through the next phase of late stage development with the objective of reaching eventual commercialisation of our proprietary assets.

The properties of our xCDNF lead candidates suggest exciting potential for drug development even beyond Parkinson’s disease.